FDA Cancer Drug IND Exemptions Clarified In Draft Guidance
FDA is seeking to reduce the number of unnecessary IND submissions it receives by issuing a draft guidance clarifying IND exemptions for oncologic products
You may also be interested in...
FDA has revised its guidance on IND exemptions for marketed cancer drugs to allow some large randomized trials to qualify
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011